Urgent.News

What's breaking now, across thousands of outlets.

More in Health & Medicine

The FDA Must End Unnecessary Drug Trials | Opinion

The Food and Drug Administration should cut biosimilar trials to reduce costs, boost competition and improve patient access.

  • FDA drafts recommendations to streamline PK testing, potentially saving 50% costs.
  • Comparative efficacy studies may be redundant with other evidence establishing biosimilarity.
  • Regulators must adopt evidence-based guidelines excluding routine trials for biosimilars.

More from Friday 16 October →